Simulations Plus, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2024, the three months ended November 30, 2023; comparative period is the three months ended November 30, 2022. Simulations Plus develops drug-discovery and development modeling software and provides consulting services. Results include Immunetrics, acquired in June 2023. The company reorganized internally around product and service business units at the start of fiscal 2024.
Financial performance
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $14.5m | $12.0m | +21% |
| Gross profit / margin | $9.8m / 68% | $9.3m / 78% | Profit +6%; margin down 10 points |
| Operating income / margin | $1.0m / 7% | $0.9m / 7% | +9% |
| Other income | $1.4m | $0.7m | +95% |
| Net income / diluted EPS | $1.9m / $0.10 | $1.2m / $0.06 | Net income +56% |
| Cash from operations | $0.2m | $4.7m | Down $4.5m |
- Revenue mix: Software revenue grew 25% to $7.6m, led by GastroPlus and QSP Thales oncology-model software. Services revenue grew 17% to $6.9m, primarily reflecting Immunetrics and QSP services.
- Margins: Software gross margin was 87%, up from 85%; services gross margin was 47%, down from 70%. Management attributed the services cost increase partly to the reorganization ($1.2m) and Immunetrics headcount ($0.4m); it said prior-year services margin would have been 49% under the current structure. Total operating expenses increased 6% to $8.9m.
- Other income and taxes: Other income included $1.3m interest income, a $0.1m favorable contingent-consideration revaluation, and $0.04m foreign-exchange gain. The effective tax rate was 19%, versus 23%, primarily due to disqualifying dispositions of incentive stock options.
Financial position and cash flows
- At November 30, 2023, cash and equivalents were $39.8m and short-term investments were $74.1m; together they totaled $113.9m. Working capital was $121.1m.
- Total assets were $185.8m and total liabilities were $13.4m. The filing reports no conventional borrowing; liabilities included $6.5m in contracts payable related to the Immunetrics transaction and $1.1m in operating lease liabilities.
- Operating cash flow was $0.2m, versus $4.7m a year earlier. Management cited operating-asset and liability movements, including bonus-payment and payroll timing; the prior-year comparison benefited from customer collections on older receivables.
- Investing cash outflow was $16.9m, mainly reflecting net purchases of short-term investments and $0.9m of capitalized software-development costs. Financing cash outflow was $1.0m, primarily the $1.2m dividend payment. Cash decreased $17.7m during the quarter.
Outlook, risks, and notable items
- The filing provides no quantified revenue, earnings, or margin guidance. Management said existing capital and expected operating funds should cover foreseeable working-capital and capital needs, including the option to use the remaining $30m authorized under its share-repurchase program.
- Management expects demand for productivity-enhancing modeling and simulation tools to support adoption, but cautioned that new products may not produce material growth. Customer delays, program holds or cancellations, industry consolidation, competition, economic uncertainty, inflation, interest rates, and geopolitical instability could affect results.
- The Immunetrics acquisition includes potential earnout payments of up to $8.0m tied to 2023 and 2024 revenue milestones, plus a $1.8m holdback subject to adjustments and indemnification obligations. The first earnout amount had not been determined at quarter-end.
- The company declared a subsequent quarterly dividend of $0.06 per share, payable February 5, 2024. A proposed increase in shares authorized under the 2021 equity plan, from 1.55m to 2.5m, was subject to shareholder approval at the February 2024 annual meeting.
- No material litigation, impairment losses, material changes to previously disclosed risk factors, or material changes in internal control were reported. Management concluded disclosure controls were effective.
Investor verification points
- Assess whether software growth continues and whether services utilization improves after the internal reorganization and Immunetrics integration.
- Monitor services and consolidated gross margins, given the significant year-over-year margin decline.
- Track operating cash conversion and working-capital movements alongside reported net income.
- Review Immunetrics milestone performance, the final earnout calculation, and settlement of the holdback.
- Confirm shareholder approval and potential dilution effects of the proposed equity-plan increase; also monitor any future repurchases and dividend declarations.